Study to Assess Efficacy and Safety of Aclidinium Bromide and Aclidinium Bromide/Formoterol Fumarate in Stabile COPD Patients (AVANT)

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: COPD

Treatments: Drug: Aclidinium bromide/formoterol Fixed-Dose Combination; Drug: Formoterol Fumarate; Drug: Placebo; Drug: Aclidinium bromide

Study type: Interventional

Funder types: Industry

Identifiers

NCT03022097

D6570C00002

M-AS464-30 (Other Identifier)

Details and patient eligibility

About

This is a multiple dose, randomised, parallel, double blind, double dummy, multicentre and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide/Formoterol fumarate compared with individual components and placebo and Aclidinium bromide compared with Placebo when administered to patients with stable Chronic Obstructive Pulmonary Disease (COPD).

Enrollment: 1,625 patients

Sex: All

Ages: 40 to 130 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Adult male or non-pregnant, non-lactating female patients aged ≥40
• 2. Patients with a diagnosis of COPD prior to Visit 1 (screening)
• 3. Patients with moderate to severe stable COPD (Stage II or Stage III) at Visit 1: post-bronchodilator FEV1 ≥30% and < 80% and post-bronchodilator FEV1/Forced vital capacity (FVC) < 70%
• 4. Current or former smokers with a smoking history of ≥ 10 pack-years
• 5. Patients able to perform repeatable pulmonary function testing for FEV1 according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2005 criteria at Visit 1(screening)
• 6. Patients who understand the study procedures and are willing to participate in the study as indicated by signing the informed consent

Exclusion criteria

• 1. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or site staff) or patients employed by or relatives of the employees of the site or sponsor.
• 2. Previous enrolment or randomisation in the present study
• 3. History or current diagnosis of asthma
• 4. Any respiratory tract infection (including the upper respiratory tract) or COPD exacerbation (including the mild COPD exacerbation) within 6 weeks prior to screening or during the run-in period
• 5. Patients hospitalized for COPD exacerbation (an emergency room visit for longer than 24 hours will be considered a hospitalization) within 3 months prior to screening and during the run-in period
• 6. Clinically significant respiratory conditions other than COPD
• 7. Patients who in the Investigator's opinion may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to screening
• 8. Use of long-term oxygen therapy (≥15 hours/day)
• 9. Patient who does not maintain regular day/night, waking/sleeping cycles including night shift workers
• 10. Clinically significant cardiovascular conditions
• 11. Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension
• 12. Patients with QT corrected interval (QTc) using Fridericia formula (QTcF) (QTc=QT/ Duration in milliseconds between two R peaks of two consecutive QRS complexes (RR1/3) >470 msec as indicated in the centralised reading report assessed at Screening (Visit 1)
• 13. Patients with clinically significant abnormalities in the clinical laboratory tests, ECG parameters (other than QTcF) or in the physical examination at Visit 1 (screening)
• 14. Patients with abnormal liver function tests defined as Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), or total bilirubin ≥ 2.5 times upper limit of normal ranges at screening
• 15. Patient with known non-controlled history of infection with human immunodeficiency virus and/or active hepatitis
• 16. Patient with a history of hypersensitivity reaction to inhaled anticholinergic drugs, sympathomimetic amines, inhaled medication or any component thereof
• 17. Patient with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic non-stable prostatic hypertrophy
• 18. History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer
• 19. Any other serious or uncontrolled physical or mental dysfunction
• 20. Patients with a history (within 2 years prior to Visit 1 (screening) of drug and/or alcohol abuse that may prevent study compliance based on the Investigator judgment
• 21. Patients unlikely to be cooperative or cannot comply with the study procedures
• 22. Patients treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to screening
• 23. Patients who intended to use any concomitant medication not permitted by this protocol or who had not undergone the required washout period for a particular prohibited medication
• 24. Patients unable to give consent, or patients of consenting age but under guardianship, or vulnerable patients
• 25. Any other conditions that, in the Investigator's opinion, might have indicated the patient to be unsuitable for the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

1,625 participants in 4 patient groups, including a placebo group

Experimental 1

Experimental group

Description:

Aclidinium bromide 400μg/Formoterol fumarate 12 μg

Treatment:

Drug: Aclidinium bromide/formoterol Fixed-Dose Combination

Experimental 2

Experimental group

Description:

Aclidinium bromide 400 μg

Treatment:

Drug: Aclidinium bromide

Comparator

Active Comparator group

Description:

Formoterol fumarate 12 μg

Treatment:

Drug: Formoterol Fumarate

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo